Portfolio company
BOOST Pharma
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops an off-the-shelf therapy to treat children born with severe osteogenesis imperfecta, also known as brittle bone disease.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Mereo BioPharma
The company develops clinical-stage therapies for patients with rare diseases, including osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease.
Kindling Bio
This company develops a gene therapy platform that engineers tumour cells to display markers for the immune system to treat children with solid tumours.
Genespire
This company develops off-the-shelf gene therapies for children and adults affected by inherited metabolic diseases and primary immunodeficiencies.
Epicyt Pharma
This company develops pharmaceutical treatments to restore intestinal calcium absorption for patients with osteoporosis or those who have undergone gastric bypass surgery.
Castle Creek Biosciences
This company develops cell and gene therapies for patients suffering from rare genetic skin and connective tissue diseases.
Angitia Biopharmaceuticals
The company develops biologic therapies for patients with serious musculoskeletal diseases, including osteoporosis and osteogenesis imperfecta.
Novadip Biosciences
This company develops regenerative tissue products to treat patients with large bone defects, non-union fractures and spinal fusion requirements.
EpiBone
This company grows personalized bone and cartilage grafts from a patient's own stem cells to treat individuals with skeletal defects.